Literature DB >> 19540005

Cardiac sarcoidosis complicated with atrioventricular block and wall thinning, edema and fibrosis in left ventricle: confirmed recovery to normal sinus rhythm and visualization of edema improvement by administration of predonisolone.

Shohko Miyazaki, Nobusada Funabashi, Toshio Nagai, Masae Uehara, Akihisa Kataoka, Hiroyuki Takaoka, Marehiko Ueda, Issei Komuro.   

Abstract

A 65 year-old female had a node of some kind in her right leg five years ago and was diagnosed with sarcoidosis by gallium scintigraphy. Serum angiotension-converting enzyme levels had gradually increased, and three months ago she felt palpitations and dizziness when standing. On electrocardiogram, 2:1 atrioventricular (AV) block was observed. On transthoracic echocardiogram, the basal portion of the interventricular septum (IVS) revealed wall thinning with dyskinetic motion and lack of systolic thickening, and low attenuation. The basal portion of the left ventricular (LV) posterior inferior wall revealed mild wall thickening with low attenuation. Enhanced multislice-CT revealed a thickened LV posterior wall and thinned basal portion of IVS with interstitial change suggesting presence of fibrosis or edema. Late enhancement was also observed in the basal portion of the LV posterior inferior wall and basal IVS in T1 weighted magnetic resonance imaging (MRI); in addition, an area, the center of which indicated low attenuation surrounded by high attenuation, was observed in the basal portion of the LV posterior inferior wall in T2 weighted MRI. Positron emission tomography (PET) imaging using F-18 fluoro-deoxyglucose with the subject fasted for 6 h beforehand, revealed strong uptake in the basal portion of IVS and a thickened LV posterior wall, suggesting the presence of inflammation. Administration of predonisolone was started before pacemaker implantation and clinical symptoms immediately disappeared; in addition AV block recovered to normal sinus rhythm. On a repeat MRI performed four months later, the late enhancement in T1 weighted MRI and the high attenuation surrounding low attenuation in the basal portion of the LV posterior inferior wall in T2 weighted MRI both disappeared, and we confirmed that temporary edema had also disappeared.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540005     DOI: 10.1016/j.ijcard.2009.05.047

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Elevated (18)F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis.

Authors:  Osamu Manabe; Hiroshi Ohira; Keiichiro Yoshinaga; Takahiro Sato; Alisa Klaipetch; Noriko Oyama-Manabe; Yoichi M Ito; Ichizo Tsujino; Masaharu Nishimura; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-29       Impact factor: 9.236

Review 2.  Clinical Importance of Myocardial T2 Mapping and Texture Analysis.

Authors:  Yasuo Amano; Yuko Omori; Chisato Ando; Fumi Yanagisawa; Yasuyuki Suzuki; Xiaoyan Tang; Hiroko Kobayashi; Ryo Takagi; Naoya Matsumoto
Journal:  Magn Reson Med Sci       Date:  2020-05-11       Impact factor: 2.471

3.  Improved Diagnostic Performance of New-generation 320-slice Computed Tomography with Forward-projected Model-based Iterative Reconstruction SoluTion for the Assessment of Late Enhancement in Left Ventricular Myocardium.

Authors:  Hiroyuki Takaoka; Masae Uehara; Yuichi Saito; Joji Ota; Yasunori Iida; Manami Takahashi; Koichi Sano; Issei Komuro; Yoshio Kobayashi
Journal:  Intern Med       Date:  2020-06-02       Impact factor: 1.271

4.  Diagnostic and predictive value of speckle tracking echocardiography in cardiac sarcoidosis.

Authors:  Cristina Di Stefano; Giulia Bruno; Maria C Arciniegas Calle; Gayatri A Acharya; Lynn M Fussner; Patompong Ungprasert; Leslie T Cooper; Lori A Blauwet; Jay H Ryu; Patricia A Pellikka; Eva M Carmona Porquera; Hector R Villarraga
Journal:  BMC Cardiovasc Disord       Date:  2020-01-20       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.